{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:44:20Z","timestamp":1790315060836,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ningbo Medical Science and Technology Project","award":["2013A27"],"award-info":[{"award-number":["2013A27"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Prognosis in malignant peritoneal mesothelioma (MPM) remains poor, and the associated factors are unclear. Therefore, this study aimed to investigate the prognostic factors of MPM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 52 female MPM patients treated in 2012\u20132017 were retrospectively analyzed. Kaplan-Meier survival curves were generated for survival analysis by the log-rank test. The Cox regression model was used for univariate and multivariate analyses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Univariate analysis showed that median survival time (MST) was longer in the epithelioid type compared with the sarcomatoid type (12 months vs 5 months); cumulative survival rates at 12 months were 45.7% and 0%, respectively (<jats:italic>P=<\/jats:italic>0.005). MST was longer in patients with proliferating cell nuclear antigen (Ki67) \u2264 10% compared with those with Ki67 &gt; 10% (15 months vs 11 months). Cumulative survival rates at 12 months were 60.0% and 28.1%, respectively (<jats:italic>P=<\/jats:italic>0.036). MSTs in patients administered peritoneal biopsy or adnexectomy + paclitaxel + platinum perfusion, peritoneal biopsy (or adnexectomy) + pemetrexed + platinum perfusion, cytoreductive surgery + paclitaxel + platinum perfusion, and cytoreductive surgery + pemetrexed + platinum perfusion were 6, 11, 12, and 24 months, respectively, with cumulative survival rates at 12 months of 0%, 35.7%, 45.5%, and 73.3%, respectively. Survival time after cytoreductive surgery combined with pemetrexed + platinum was the longest. In multivariate analysis, pathological type, T staging, and therapeutic regimen were independent prognostic factors of MPM (<jats:italic>P &lt;<\/jats:italic> 0.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Prognosis in MPM is associated with pathological subtype, clinical staging, cytoreductive surgery, and subsequent pemetrexed use. Radical cytoreductive surgery and postoperative use of pemetrexed prolong survival.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12957-022-02688-x","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T02:02:49Z","timestamp":1656468169000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prognostic factors of malignant peritoneal mesothelioma: a retrospective study of 52 female patients"],"prefix":"10.1186","volume":"20","author":[{"given":"Jianting","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,29]]},"reference":[{"key":"2688_CR1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/jgh.13260","volume":"31","author":"YF Liang","year":"2016","unstructured":"Liang YF, Zheng GQ, Chen YF, Song H, Yin WJ, Zhang L. CT differentiation of diffuse malignant peritoneal mesothelioma and peritoneal carcinomatosis. J Gastroenterol Hepatol. 2016;31:709\u201315.","journal-title":"J Gastroenterol Hepatol"},{"key":"2688_CR2","first-page":"599","volume":"52","author":"SC Wei","year":"2013","unstructured":"Wei SC, Zheng GQ, Wang ZG, Xu XJ, Liu JK, Yang YX, et al. Retrospective analysis of clinical data of 162 cases of peritoneal malignant mesothelioma in Cangzhou. Chin J Intern Med. 2013;52:599\u2013601.","journal-title":"Chin J Intern Med"},{"key":"2688_CR3","doi-asserted-by":"publisher","first-page":"236","DOI":"10.21037\/atm.2017.03.96","volume":"5","author":"J Kim","year":"2017","unstructured":"Kim J, Bhagwandin S, Labow DM. Malignant peritoneal mesothelioma: a review. Ann Transl Med. 2017;5:236.","journal-title":"Ann Transl Med"},{"key":"2688_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1179\/2049396712Y.0000000016","volume":"19","author":"SJ Henley","year":"2013","unstructured":"Henley SJ, Larson TC, Wu M, Antao VC, Lewis M, Pinheiro GA, et al. Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003-2008. Int J Occup Environ Health. 2013;19:1\u201310.","journal-title":"Int J Occup Environ Health"},{"key":"2688_CR5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.gcb.2010.07.016","volume":"35","author":"H Sharma","year":"2011","unstructured":"Sharma H, Bell I, Schofield J, Bird G. Primary peritoneal mesothelioma: case series and literature review. Clin Res Hepatol Gastroenterol. 2011;35:55\u20139.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"2688_CR6","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12957-019-1731-4","volume":"17","author":"D Klos","year":"2019","unstructured":"Klos D, Ri\u0161ko J, Love\u010dek M, Skalick\u00fd P, Svobodov\u00e1 I, Krej\u010d\u00ed D, et al. Trends in peritoneal surface malignancies: evidence from a Czech nationwide population-based study. World J Surg Oncol. 2019;17:182.","journal-title":"World J Surg Oncol"},{"key":"2688_CR7","first-page":"2336","volume":"91","author":"HJ Shao","year":"2011","unstructured":"Shao HJ, Ma JT, Yang XE, Xu LP, Yang CL. Diagnostic and therapeutic analyses for peritoneal malignant mesothelioma: a report of 26 women. Natl Med J China. 2011;91:2336\u20139.","journal-title":"Natl Med J China"},{"issue":"Suppl 4","key":"2688_CR8","first-page":"S397","volume":"5","author":"K Porpodis","year":"2013","unstructured":"Porpodis K, Zarogoulidis P, Boutsikou E, Papaioannou A, Machairiotis N, Tsakiridis K, et al. Malignant pleural mesothelioma: current and future perspectives. J Thorac Dis. 2013;5(Suppl 4):S397\u2013406.","journal-title":"J Thorac Dis"},{"key":"2688_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12957-022-02604-3","volume":"20","author":"HL Wu","year":"2022","unstructured":"Wu HL, Yang ZR, Yan LJ, Su YD, Ma R, Li Y. NPM2 in malignant peritoneal mesothelioma: from basic tumor biology to clinical medicine. World J Surg Oncol. 2022;20:141.","journal-title":"World J Surg Oncol"},{"key":"2688_CR10","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12957-021-02276-5","volume":"19","author":"S Deo","year":"2021","unstructured":"Deo S, Ray M, Bansal B, Bhoriwal S, Bhatnagar S, Garg R, et al. Feasibility and outcomes of cytoreductive surgery and HIPEC for peritoneal surface malignancies in low- and middle-income countries: a single-center experience of 232 cases. World J Surg Oncol. 2021;19:164.","journal-title":"World J Surg Oncol"},{"key":"2688_CR11","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12957-018-1377-7","volume":"16","author":"HJ Yoo","year":"2018","unstructured":"Yoo HJ, Hong JJ, Ko YB, Lee M, Kim Y, Han HY, et al. Current practices of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies: an international survey of oncologic surgeons. World J Surg Oncol. 2018;16:92.","journal-title":"World J Surg Oncol"},{"key":"2688_CR12","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12957-020-01956-y","volume":"18","author":"J Jiao","year":"2020","unstructured":"Jiao J, Li C, Yu G, Zhang L, Shi X, Yan J, et al. Efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of malignant ascites. World J Surg Oncol. 2020;18:180.","journal-title":"World J Surg Oncol"},{"key":"2688_CR13","doi-asserted-by":"publisher","first-page":"433","DOI":"10.4149\/neo_2014_053","volume":"61","author":"H Kaya","year":"2014","unstructured":"Kaya H, Sezgi C, Tanrikulu AC, Taylan M, Abakay O, Sen HS, et al. Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma. Neoplasma. 2014;61:433\u20138.","journal-title":"Neoplasma"},{"key":"2688_CR14","first-page":"659","volume":"31","author":"S Boussios","year":"2018","unstructured":"Boussios S, Moschetta M, Karathanasi A, Tsiouris AK, Kanellos FS, Tatsi K, et al. Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives. Ann Gastroenterol. 2018;31:659\u201369.","journal-title":"Ann Gastroenterol"},{"key":"2688_CR15","doi-asserted-by":"publisher","first-page":"647","DOI":"10.5858\/arpa.2012-0214-OA","volume":"137","author":"AN Husain","year":"2013","unstructured":"Husain AN, Colby T, Ordonez N, Krausz T, Attanoos R, Beasley MB, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2013;137:647\u201367.","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"2688_CR16","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ejso.2020.02.011","volume":"47","author":"S Kusamura","year":"2021","unstructured":"Kusamura S, Kepenekian V, Villeneuve L, Lurvink RJ, Govaerts K, De Hingh IHJT, et al. Peritoneal mesothelioma: PSOGI\/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol. 2021;47(1):36\u201359. https:\/\/doi.org\/10.1016\/j.ejso.2020.02.011 Epub 2020 Mar 12. PMID: 32209311.","journal-title":"Eur J Surg Oncol"},{"key":"2688_CR17","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359\u201374.","journal-title":"Cancer Treat Res"},{"key":"2688_CR18","first-page":"198","volume":"42","author":"Y Li","year":"2015","unstructured":"Li Y, Feng ZY, Liang H, Wang HQ, Hao JH, Zhu ZG, et al. Introduction for expert consensus on cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal surface malignancies. Chin. J Clin Oncol. 2015;42:198\u2013206.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2688_CR19","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3390\/diagnostics10060386","volume":"10","author":"F Pezzuto","year":"2020","unstructured":"Pezzuto F, Serio G, Fortarezza F, Scattone A, Caporusso C, Punzi A, et al. Prognostic Value of Ki67 percentage, WT-1 expression and p16\/CDKN2A deletion in diffuse malignant peritoneal mesothelioma: a single-centre cohort study. Diagnostics (Basel). 2020;10(6):386. https:\/\/doi.org\/10.3390\/diagnostics10060386 PMID: 32526924; PMCID: PMC7345555.","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"2688_CR20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13000-021-01125-z","volume":"16","author":"F Pezzuto","year":"2021","unstructured":"Pezzuto F, Vimercati L, Fortarezza F, Marzullo A, Pennella A, Cavone D, et al. Evaluation of prognostic histological parameters proposed for pleural mesothelioma in diffuse malignant peritoneal mesothelioma. A short report. Diagn Pathol. 2021;16(1):64. https:\/\/doi.org\/10.1186\/s13000-021-01125-z PMID: 34294087; PMCID: PMC8296535.","journal-title":"Diagn Pathol"},{"issue":"4","key":"2688_CR21","first-page":"411","volume":"3","author":"K Pillai","year":"2013","unstructured":"Pillai K, Pourgholami MH, Chua TC, Morris DL. Ki67-BCL2 index in prognosis of malignant peritoneal mesothelioma. Am J Cancer Res. 2013;3(4):411\u201323 PMID: 23977450; PMCID: PMC3744020.","journal-title":"Am J Cancer Res"},{"issue":"5","key":"2688_CR22","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1245\/s10434-015-4962-9","volume":"23","author":"S Kusamura","year":"2016","unstructured":"Kusamura S, Torres Mesa PA, Cabras A, Baratti D, Deraco M. The role of Ki-67 and pre-cytoreduction parameters in selecting diffuse malignant peritoneal mesothelioma (DMPM) patients for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2016;23(5):1468\u201373. https:\/\/doi.org\/10.1245\/s10434-015-4962-9 Epub 2015 Nov 16. PMID: 26572754.","journal-title":"Ann Surg Oncol"},{"key":"2688_CR23","first-page":"2000","volume":"41","author":"N Li","year":"2019","unstructured":"Li N, Chen ZJ, Gao Y, Mao WM. Analysis of clinical characteristics and prognosis of malignant peritoneal mesothelioma. Zhejiang Med J. 2019;41:2000\u20132.","journal-title":"Zhejiang Med J"},{"key":"2688_CR24","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3390\/ijms19010238","volume":"19","author":"B Tolani","year":"2018","unstructured":"Tolani B, Acevedo LA, Hoang NT, He B. Heterogeneous contributing factors in MPM disease development and progression: biological advances and clinical implications. Int J Mol Sci. 2018;19:238.","journal-title":"Int J Mol Sci"},{"key":"2688_CR25","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jtho.2017.09.1968","volume":"13","author":"NS Patil","year":"2018","unstructured":"Patil NS, Righi L, Koeppen H, Zou W, Izzo S, Grosso F, et al. Molecular and histopathological characterization of the tumor immune microenvironment in advanced stage of malignant pleural mesothelioma. J Thorac Oncol. 2018;13:124\u201333.","journal-title":"J Thorac Oncol"},{"key":"2688_CR26","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1093\/annonc\/mdl345","volume":"18","author":"P Boffetta","year":"2007","unstructured":"Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol. 2007;18:985\u201390.","journal-title":"Ann Oncol"},{"key":"2688_CR27","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1093\/jnci\/95.1.38","volume":"95","author":"HD Strickler","year":"2003","unstructured":"Strickler HD, Goedert JJ, Devesa SS, Lahey J, Fraumeni JF Jr, Rosenberg PS. Trends in U.S. pleural mesothelioma incidence rates following simian virus 40 contamination of early poliovirus vaccines. J Natl Cancer Inst. 2003;95:38\u201345.","journal-title":"J Natl Cancer Inst"},{"key":"2688_CR28","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1136\/oem.51.12.804","volume":"51","author":"R Spirtas","year":"1994","unstructured":"Spirtas R, Heineman EF, Bernstein L, Beebe GW, Keehn RJ, Stark A, et al. Malignant mesothelioma: attributable risk of asbestos exposure. Occup Environ Med. 1994;51:804\u201311.","journal-title":"Occup Environ Med"},{"key":"2688_CR29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.4240\/wjgs.v1.i1.38","volume":"1","author":"S Munkholm-Larsen","year":"2009","unstructured":"Munkholm-Larsen S, Cao CQ, Yan TD. Malignant peritoneal mesothelioma. World J Gastrointest Surg. 2009;1:38\u201348.","journal-title":"World J Gastrointest Surg"},{"key":"2688_CR30","first-page":"2196","volume":"21","author":"YF Liang","year":"2018","unstructured":"Liang YF, Zheng GQ, Li CY, Sun NN, Guo ZJ. Investigation of the prognostic factors in malignant peritoneal mesothelioma. Chin Gen Prac. 2018;21:2196\u2013200.","journal-title":"Chin Gen Prac"},{"key":"2688_CR31","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/annonc\/mdl428","volume":"18","author":"TD Yan","year":"2007","unstructured":"Yan TD, Welch L, Black D, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol. 2007;18:827\u201334.","journal-title":"Ann Oncol"},{"key":"2688_CR32","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1001\/archsurg.138.1.26","volume":"138","author":"P Shen","year":"2003","unstructured":"Shen P, Levine EA, Hall J, Case D, Russell G, Fleming R, et al. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg. 2003;138:26\u201333.","journal-title":"Arch Surg"},{"key":"2688_CR33","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1097\/COC.0b013e3182a0e867","volume":"38","author":"K Pillai","year":"2015","unstructured":"Pillai K, Pourgholami MH, Chua TC, Morris DL. Prognostic significance of Ki67 expression in malignant peritoneal mesothelioma. Am J Clin Oncol. 2015;38:388\u201394.","journal-title":"Am J Clin Oncol"},{"key":"2688_CR34","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.1245\/s10434-015-4498-z","volume":"22","author":"M Deraco","year":"2015","unstructured":"Deraco M, Cabras A, Baratti D, Kusamura S. Immunohistochemical evaluation of Minichromosome maintenance protein 7 (MCM7), topoisomerase IIalpha, and Ki-67 in diffuse malignant peritoneal mesothelioma patients using tissue microarray. Ann Surg Oncol. 2015;22:4344\u201351.","journal-title":"Ann Surg Oncol"},{"key":"2688_CR35","first-page":"1139","volume":"48","author":"YF Liang","year":"2019","unstructured":"Liang YF, Zheng GQ, Li CY, Sun NN, Guo ZJ. Prognostic significance of Ki67, MCM2, ERCC1 and FLI-1 expression in malignant peritoneal mesothelioma. Chongqing Med. 2019;48:1139\u201344.","journal-title":"Chongqing Med"},{"key":"2688_CR36","first-page":"211","volume":"40","author":"NN Li","year":"2018","unstructured":"Li NN, Bai CM, Wang YY, Ge YP, Zhao L. Clinical analysis of 25 cases of malignant peritoneal mesothelioma. Acta Acad Med Sin. 2018;40:211\u20138.","journal-title":"Acta Acad Med Sin"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-022-02688-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-022-02688-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-022-02688-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T02:03:09Z","timestamp":1656468189000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-022-02688-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,29]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2688"],"URL":"https:\/\/doi.org\/10.1186\/s12957-022-02688-x","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,29]]},"assertion":[{"value":"4 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Medical Ethics Committee of Yuyao People's Hospital in Zhejiang Province (Approval number: 2021-08-001; Date: August 19, 2021). Informed consent was waived due to the retrospective design.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"219"}}